Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Annexon Temettü

Temettü kriter kontrolleri 0/6

Annexon şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.09
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ANNX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ANNX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Annexon Piyasaya Karşı Temettü Getirisi

ANNX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ANNX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (ANNX) (3 yıla kadar)	0%

Önemli Temettü: ANNX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ANNX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ANNX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ANNX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Annexon Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Annexon, Inc. Announces Management Appointments

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon, Inc. Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Annexon, Inc. Announces Executive Changes

Independent Director has left the company

New 90-day high: US$33.04

Independent Director has left the company

Independent Chairman William Young has left the company

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

New 90-day low: US$22.00

New 90-day high: US$30.55

Annexon, Inc. Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome